KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of <em>BRCA1</em> and <em>BRCA2</em> (CIMBA)

Berchuck, Andrew

60
KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)

Tuesday, March 31, 2015: 10:29 AM

International Ballroom (Hilton Chicago)

A. Berchuck¹, F. H. van der Baan², S. E. Johnatty³, G. Chenevix-Trench⁴, P. D. P. Pharoah⁵, M. A. Rookus² and E. Goode⁶
¹Duke University Medical Center, Durham, NC, ²Netherlands Cancer Institute, Amsterdam, Netherlands, ³Department of Genetics, Brisbane, Australia, ⁴Queensland Institute of Medical Research, Brisbane, Australia, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Mayo Clinic, Rochester, MN

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

60
KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)

60 KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)

60
KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)